




RealRate

PHARMACEUTICAL 2022

VYNE Therapeutics Inc
Rank 330 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of VYNE Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 54% points. The greatest weakness of VYNE Therapeutics Inc is the variable Expenses, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 64% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	63,186
Cost of Goods Sold	3,348
Intangible Assets	0
Liabilities, Current	18,410
Liabilities, Non-Current	0
Other Assets	3,506
Other Compr. Net Income	0
Other Expenses	5,162
Other Liabilities	0
Other Net Income	-135
Other Revenues	14,755
Property and Equipment	354
Research and Development	24,958
Selling, General and Administrative Expense	54,481

Output Variable	Value in 1000 USD
Assets	67,046
Liabilities	18,410
Expenses	87,949
Revenues	14,755
Stockholders Equity	48,636
Net Income	-73,329
Comprehensive Net Income	-73,329
BaseVar	94,148
ECR before Limited Liability	77%
Economic Capital Ratio	211%